https://scholars.lib.ntu.edu.tw/handle/123456789/551133
標題: | Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir | 作者: | Wang C.-C. Tseng K.-C. Peng C.-Y. Hsieh T.-Y. Lin C.-L. TUNG-HUNG SU TAI-CHUNG TSENG Hsu C.-S. Lin H.H. JIA-HORNG KAO |
公開日期: | 2013 | 出版社: | Blackwell Publishing | 卷: | 28 | 期: | 1 | 起(迄)頁: | 46-50 | 來源出版物: | Journal of Gastroenterology and Hepatology (Australia) | 摘要: | Background and Aim: Although entecavir has been shown to have good efficacy and low resistance for the treatment of chronic hepatitis B (CHB), factors associated with a favorable response remain unknown. Methods: This was a retrospective, multicenter study of 248 treatment-na?ve hepatitis B e antigen (HBeAg)-positive patients (69.4% male; median age, 39.4 years) treated with entecavir for more than 1 year, and 15.7% of them had cirrhosis at baseline. The primary endpoints were HBeAg loss and/or seroconversion. Results: The median baseline levels of alanine aminotransferase (ALT) and hepatitis B virus (HBV) DNA were 201U/L (range, 27-2415U/L) and 7.6 log10 IU/mL (range, 2.2-13.18), respectively. The median treatment period was 25.3 months (range, 12-69.6). The rates of ALT normalization at years 1, 2, and 3 were 83.1%, 87.9%, and 94.9%, respectively. The cumulative rates of HBeAg loss at years 1, 2, and 3 were 20.3%, 38.0%, and 48.9%, respectively. The rates of undetectable HBV-DNA at years 1, 2, and 3 were 52.1%, 78.9%, and 82.5%, respectively. Using Cox proportional hazards model, multivariate analysis showed that baseline ALTgreater than five times the upper limit of normal, and viral load were independent factors associated with HBeAg loss (hazard ratio: 1.81, and 0.812; 95% confidence interval: 1.062-3.085; 0.7-0.942, respectively). Conclusion: Entecavir treatment for 3 years can achieve good biochemical and virologic responses in HBeAg-positive CHB patients, but has a modest effect on HBeAg loss and/or seroconversion. In addition, baseline serum ALT and HBV-DNA levels are independent factors associated with favorable treatment responses. ? 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871641910&doi=10.1111%2fj.1440-1746.2012.07269.x&partnerID=40&md5=026e598675a0687a8f06049b327b8266 https://scholars.lib.ntu.edu.tw/handle/123456789/551133 |
ISSN: | 0815-9319 | DOI: | 10.1111/j.1440-1746.2012.07269.x | SDG/關鍵字: | alanine aminotransferase; entecavir; hepatitis B(e) antigen; virus DNA; adult; alanine aminotransferase blood level; antiviral therapy; article; chronic hepatitis; chronic hepatitis B; correlation analysis; female; hepatitis B; human; liver cirrhosis; major clinical study; male; priority journal; proportional hazards model; retrospective study; seroconversion; serology; virus load |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。